Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
31.16
+1.69 (5.75%)
Jun 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.80 - 31.70
52 week 6.51 - 34.03
Open 30.33
Vol / Avg. 0.00/2.66M
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -2.85
Shares 35.15M
Beta 1.00
Inst. own 81%
Aug 3, 2015
Q2 2015 Heron Therapeutics Inc Earnings Release (Estimated) Add to calendar
Jun 23, 2015
Heron Therapeutics Inc at JMP Securities Life Sciences Conference
Jun 1, 2015
Heron Therapeutics Inc at Jefferies Global Healthcare Conference
May 29, 2015
Heron Therapeutics SUSTOL MAGIC Study Phase 3 Results Conference Call - Webcast
May 14, 2015
Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 8, 2015
Q1 2015 Heron Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -121.06% -100.08%
Return on average equity -148.58% -115.70%
Employees 59 -
CDP Score - -

Address

123 SAGINAW DRIVE
REDWOOD CITY, CA 94063
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company's product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Company's other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Robert H. Rosen President, Director
Age: 59
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Brian G Drazba Chief Financial Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Paul G. Marshall Senior Vice President - Technical Operations
Age: 55
Bio & Compensation  - Reuters
Esme C. Smith Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 54
Bio & Compensation  - Reuters
Craig A. Johnson Independent Director
Age: 53
Bio & Compensation  - Reuters
Kimberly J. Manhard Independent Director
Age: 55
Bio & Compensation  - Reuters
John W. Poyhonen Independent Director
Age: 55
Bio & Compensation  - Reuters